George Brown
Non-small cell lung cancer (NSCLC) accounts for around 27% of all cancer-related deaths worldwide, making it a major public health concern. Healing necessitates the complete and permanent removal of the tumour (generally by surgery or radiation [RT]), while significant shrinkage (usually by systemic therapy) may result in long-term disease control. In the absence of treatments, host-tumor interactions, which are major factors in disease progression in the natural history, will have a considerable impact on disease progression, with treatments primarily aiming at shifting the host-tumor balance toward improvement or, if possible, healing. As a result, complete tumoral excision (and, if possible, oligometastatic sickness) remains the preferred treatment, with the goal that the host-immune response will remove microscopic residual disease, maybe with the help of systemic adjuvant medicines.
PDFShare this article
